A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.


Updates from The Motley Fool

Latest updates on Keryx Biopharmaceuticals from Fool.com.  The Fool has written over 200 articles on Keryx Biopharmaceuticals.
3 Top Stocks Under $5

Looking to pick up a lot of shares of promising businesses? Take a closer look at BioAmber, Codex...



Stock Performance

View Interactive KERX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Keryx Biopharmaceuticals.
Current Price: $6.48
Prev Close: $6.37
Open: $6.40
Bid: $6.16
Ask: $6.70
Day's Range: $6.38 - $6.56
52wk Range: $4.03 - $7.80
Volume: 1,237,801
Avg Vol 1,323,196
Market Cap: $703M
P/E (ttm): -4.75
EPS (ttm): ($1.34)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Keryx Biopharmaceuticals.
CAPS Rating 2 out of 5
 
396 Outperform
62 Underperform
CAPS All Stars
 
49 Outperform
19 Underperform

How do you think Keryx Biopharmaceuticals will perform against the market?



You pick for Keryx Biopharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Greg Madison, CEO

0% Approve

Based on 0 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Keryx Biopharmaceuticals.

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers